Merck’s Keytruda (pembrolizumab) + Eisai’s Lenvima (lenvatinib) Receives FDA’s Approval for Certain Types of Endometrial Carcinoma

 Merck’s Keytruda (pembrolizumab) + Eisai’s Lenvima (lenvatinib) Receives FDA’s Approval for Certain Types of Endometrial Carcinoma

Merck’s Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-II KEYNOTE-146/Study 111 assessing Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) in 108 patients with metastatic endometrial carcinoma that is not microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) with diseases progression following prior systemic therapy and are not candidates for curative surgery or radiation
  • The P-II KEYNOTE-146/Study 111 results: ORR (38.3%); CRR (10.6%); PRR (27.7%); median follow up time (18.7mos.). Under Project Orbis, Keytruda + Lenvima regimen is the first to receive simultaneous review decisions in the US, Australia and Canada
  • KEYTRUDA is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells. Lenvima is a kinase inhibitor targeting the activities of VEGF receptor including VEGFR1, VEGFR2 & VEGFR3

Click here to­ read full press release/ article | Ref: Merck | Image: Wsj

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post